PD-L1 immunohistochemistry in patients with non-small cell lung cancer

Affiliations

Editorial

Takanobu Jotatsu et al. J Thorac Dis. 2018 Jul.

. 2018 Jul;10(Suppl 18):S2127-S2129.

doi: 10.21037/jtd.2018.06.30.

¹ Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, Penault-Llorca F, Lantuéjoul S. Adam J, et al. Ann Oncol. 2018 Apr 1;29(4):953-958. doi: 10.1093/annonc/mdy014. Ann Oncol. 2018. PMID: 29351573

1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed
1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
1. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. 10.1016/S0140-6736(16)32517-X - DOI - PMC - PubMed